The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

A transcatheter procedure for direct modification of the aneurysmatic left ventricle

EuroIntervention 2021;16:e1541-e1543. DOI: 10.4244/EIJ-D-19-00225

1. Department of Cardiology, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China; 2. Department of Cardiac Surgery, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China; 3. Department of Anesthesia, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China; 4. Department of Ultrasound, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China; 5. Interventional Treatment Center, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China; 6. Medical Office, BioVentrix, New York, NY, USA; 7. Department of Cardiology, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China


Introduction

Left ventricular aneurysms (LVAs) are found in 10 to 30% of patients suffering from anterior myocardial infarction1. Traditionally, scar reduction has required the use of invasive surgical techniques2. The Surgical Treatment for Ischemic Heart Failure (STICH) trial is a classic trial comparing coronary artery bypass grafting (CABG) alone with a combined procedure of CABG and surgical ventricular reconstruction3. Currently, catheter-based procedures for direct modification of the left ventricle are represented by the Parachute device (CardioKinetix Inc., Menlo Park, CA, USA) and the Revivent TC™ device (BioVentrix Inc., San Ramon, CA, USA)4,5. We report our single-centre experience and outcomes ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Endovascular aortic repair in patients with challenging anatomies: the EXTREME study